Velneperit

Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity[1][2][3].

Product Specifications

CAS Number

[342577-38-2]

Product Name Alternative

S2367

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

Neuropeptide Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Velneperit.html

Purity

99.21

Solubility

DMSO : ≥ 30 mg/mL

Smiles

FC(F)(F)C1=CN=C(NC([C@H]2CC[C@H](NS(=O)(C(C)(C)C)=O)CC2)=O)C=C1

Molecular Formula

C17H24F3N3O3S

Molecular Weight

407.45

Precautions

H302, H315, H320, H335

References & Citations

[1]Ishihara A, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci U S A. 2006 May 2;103 (18) :7154-8.|[2]McCullough KM, et al. Cell-type-specific interrogation of CeA Drd2 neurons to identify targets for pharmacological modulation of fear extinction. Transl Psychiatry. 2018 Aug 22;8 (1) :164. |[3]Powell, A. G., C. M. Apovian, and L. J. Aronne. New drug targets for the treatment of obesity. Clinical pharmacology & therapeutics 90.1 (2011) : 40-51.